Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

Abstract Background Drug resistance is a major obstacle to treating cancers because it desensitizes cancer cells to chemotherapy. Recently, attention has been focused on changes in the tumor immune landscape after the acquisition of drug resistance. Programmed death-ligand-1 (PD-L1) is an immune sup...

Full description

Bibliographic Details
Main Authors: Haifang Wang, Chen Fu, Jun Du, Hongsheng Wang, Rui He, Xiaofeng Yin, Haixia Li, Xin Li, Hongxia Wang, Kui Li, Lei Zheng, Zongcai Liu, Yurong Qiu
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
PD-L1
Drug resistance
c-Jun
Histone acetylation
HDAC3
Online Access:https://doi.org/10.1186/s13046-020-1536-x

Similar Items

Similar Items